Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFG8TI)

Drug Name

INCB00928 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Anemia	3A00-3A9Z	Phase 2	[1]
Multiple myeloma	2A83	Phase 2	[1]
Myelodysplastic syndrome	2A37	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Activin receptor-like kinase 2 (ALK-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TP-0184	DMJVZBC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
PMID27774822-Compound-Figure10Compound12	DMFAGOZ	N. A.	N. A.	Patented	[4]
PMID27774822-Compound-Figure10Compound4	DMMJVTW	N. A.	N. A.	Patented	[4]
PMID23639540C13d	DMSTQGH	Discovery agent	N.A.	Investigative	[5]
PMID23639540C13a	DMLXOAQ	Discovery agent	N.A.	Investigative	[5]
PMID23639540C13r	DMHBZ0N	Discovery agent	N.A.	Investigative	[5]
LDN-214117	DM57Z8J	Discovery agent	N.A.	Investigative	[6]
ML347	DMR8N36	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Activin receptor-like kinase 2 (ALK-2)	TTJNBQA	ACVR1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04582539) To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Incyte.
3	Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
4	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
5	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
6	Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15.